<DOC>
	<DOCNO>NCT02884128</DOCNO>
	<brief_summary>This trial multi-center , open-label , phase I , dose escalation study PEP02 ( liposomal encapsulate irinotecan ) combination 5-FU LV patient advance solid tumor .</brief_summary>
	<brief_title>A Study PEP02 Combination With 5-fluorouracil ( 5-FU ) Leucovorin ( LV ) Advanced Solid Tumors</brief_title>
	<detailed_description>In study , initial start dose PEP02 60 mg/m2 , escalate increment 20 mg/m2 dose level . 5-FU LV give 24-hour infusion via implanted central venous catheter , dose fixed 2000 mg/m2 200 mg/m2 , respectively . PEP02 administer Day 1 ; 5-FU/LV start end PEP02 infusion Day 1 also Day 8 . Treatment repeat every 3 week regard one cycle treatment .</detailed_description>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor locally advance metastatic fail standard chemotherapy standard treatment available ECOG performance status 0 1 With normal organ marrow function Have major surgery , chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover toxicity due previous treatment With know suspicious primary secondary brain tumor History allergic reaction attribute compound similar chemical biologic composition PEP02 , 5FU leucovorin HBsAg+ antiHCV+ patient splenomegaly ( define spleen size &gt; 11 cm CT scan ) Uncontrolled intercurrent illness include , limited , ongoing active infection , history symptomatic congestive heart failure Functional Class II ( New York Heart Association ) ischemic heart disease ( i.e . myocardial infarction angina pectoris ) , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breast feeding female ( pregnancy test must perform female childbearing potential entering study result must negative ) Had receive irinotecan treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>